April 23, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL ® gene silencing technology to ...
Atrium Therapeutics, Inc. (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone ...
As drug candidates advance through clinical development, their value increases significantly due to rising probabilities of success and proximity to commercialization. The rise of fair-value ...
Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next ...
Creative Biolabs has further strengthened its organ-specific targeted exosome modification platform to support advanced ...
Most lipid nanoparticle (LNP) platforms face the same constraint: they are cleared rapidly by the liver, which makes it hard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results